4 Investor presentation First three months of 2023 Strategic Aspirations 2025 | High Purpose and sustainability (ESG) Progress towards zero environmental impact • Carbon emissions decreased by 21% vs Q1 2019 1 Adding value to society • Medical treatment provided to 37.2 million people living with diabetes • Reaching more than 42,000 children in Changing Diabetes ® in Children programme Being recognised as a sustainable employer • Share of women in senior leadership positions has increased to 39% from 37% end of March 2022 Diabetes value market share increased by 1.7%-points to 32.2% 2 Obesity care sales of DKK 7.8 billion (+124% at CER) Rare disease sales of DKK 4.6 billion (-16% at CER) Commercial execution 1 Scope 1,2 and partial scope 3 limited to CO2 emissions from business flights and product distribution; 2 MAT (Moving annual total) VP: Vice president; CER: Constant exchange rates; CRL: Complete Response Letter; US: United States; GHD: Growth Hormone Defici Note: The strategic aspirations are not a projection of Novo Nordisk's financial outlook or expected growth
Download PDF file